Skip to main content

NECLIFE · Nectar Lifesciences Limited · Financials

10.73 INR +0.25 (+2.39%) At close · Nov 13
Volume · Nov 13 12.7K Avg daily vol (14 sessions) 13.56K

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Revenue
0 -100%
FY2026 Revenue FY2020–FY2026
Net Income
-2.93B -157.6%
FY2026 Net Income FY2020–FY2026
Operating Cash Flow
-3.49B -305.8%
FY2026 Operating Cash Flow FY2022–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
INR 50.11M 0 16.73B 16.86B 15.25B 16.69B 15.44B 23.67B
INR 4.59M 3.43M 623.89M 607.18M 591.19M 569.68M 602.53M 607.66M
INR 362.82M 361.25M 745.78M 871.42M 794.87M 788.1M 1.12B 1.26B
INR -254.53M -878.79M -1.62B 182.69M -424.2M 340.81M -847.67M 374.71M
INR -398.19M -305.32M -478.53M 132.74M -182.37M 90.34M -115.04M 56.83M
INR -2.45B -2.93B -1.14B 0 0 0 -732.64M 317.89M
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 0 in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.